Abstract

ObjectivesTo compare the persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between patients with juvenile idiopathic arthritis (JIA) and healthy controls.MethodsMeasles, mumps, rubella (MMR) and diphtheria–tetanus toxoid (DT)-specific immunoglobulin...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Comparison of acellular pertussis-diphtheria-tetanus toxoids and Haemophilus influenzae type b vaccines administered separately vs. combined in younger vs. older toddlers.
Margaret B Rennels ... Jean Nonenmacher
The Pediatric infectious disease journal | VOL. 17
Margaret B Rennels, et. al.Margaret B Rennels ... Jean Nonenmacher
01 Feb 1998
Antibody response to accelerated immunisation with diphtheria, tetanus, pertussis vaccine
M.E.B Ramsay ... A-M Attwell
The Lancet | VOL. 342
M.E.B Ramsay, et. al.M.E.B Ramsay ... A-M Attwell
01 Jul 1993
Low cord blood pneumococcal antibody concentrations predict more episodes of otitis media.
Eric T Becken ... G Scott Giebink
Archives of otolaryngology--head & neck surgery | VOL. 127
Eric T Becken, et. al.Eric T Becken ... G Scott Giebink
01 May 2001
Concentrations of tetanus and diphtheria antibodies in vaccinated Greenlandic children aged 7–12 years exposed to marine pollutants, a cross sectional study
Clara Amalie Gade Timmermann ... Philippe Grandjean
Environmental Research | VOL. 203
Clara Amalie Gade Timmermann, et. al.Clara Amalie Gade Timmermann ... Philippe Grandjean
31 Jul 2021
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.